Mylan ($MYL) has filled out details on an expanded recall of two drugs manufactured by Bangalore-based Agila Onco, which it bought from Strides Arcolab two years ago, as the company works to fend off a takeover offer from Teva Pharmaceuticals ($TEVA), while moving on its own unsolicited bid for Perrigo ($PRGO).
Mylan notified the U.S. FDA and on its website last week that it was expanding its nationwide U.S. voluntary recall for lots of gemcitabine and methotrexate injection because of foreign particulate matter observed during testing of retention samples, DNA India newspaper reported.
Mylan, in a press release, said the gemcitabine products were distributed in the U.S. between January 2014 and February 2015. The methotrexate injection products were distributed in the U.S. between Dec, 8 and 19, 2014, the company said.
"Intrathecal administration could result in a life threatening adverse event or result in permanent impairment of a body function," Mylan said in the press statement.
In an earlier recall initiated in April, Mylan recalled one lot of the cancer drug carboplatin with a Mylan label.
Mylan is in the middle of a complicated game of M&A with its own offer for Perrigo ($PRGO), even as Teva makes a bid for Mylan.
- here's the story from DNA India
- and the Mylan release